SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
Monmouth, NJ, (May 22, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.